Incysus Ltd., of New York, submitted an IND application to the FDA for a phase I trial testing its expanded and activated allogeneic gamma-delta T cells in patients with blood cancers following haploidentical stem cell transplantation. Read More
Array Biopharma Inc., of Boulder, Colo., closed its public offering of about 24.1 million shares, including 3.1 million shares issued to cover underwriters' full overallotment option. Read More
Zymeworks Inc., of Vancouver, British Columbia, said Merck & Co. Inc., of Kenilworth, N.J., provided formal notification of its plans to advance a bispecific drug candidate into preclinical development. Read More
As part of its educational efforts on the qualification of biomarkers to potentially streamline drug development, the FDA released new modules mapping out the process for requestors and explaining the opportunities to engage with the agency during the qualification of the biomarkers. Read More
HONG KONG – Shanghai Fosun Pharmaceutical Group Co. Ltd. has made progress on its proposed purchase of the majority stake in India's Gland Pharma Ltd., with a recent amendment stating it would acquire 74 percent of the interest in the Hyderabad-based pharmaceutical company for $1.09 billion, instead of the original proposed 86 percent for $1.26 billion. Read More
A study showing that an inhibitor of WNT signaling had differential effects on the lung and bone metastasis of breast cancer could have important implications for treating breast cancer, Chinese researchers reported in the Sept. 11, 2017, online edition of Nature Cell Biology. Read More
Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with attention deficit hyperactivity disorder (ADHD) that it was evaluating in twin phase III studies. Read More
For scientists aiming to combat the long-known problem of axonal degeneration, "the issue was that there wasn't a lever to pull, there wasn't a drug target," Disarm Therapeutics Inc.'s acting CEO, Jason Rhodes, told BioWorld. Read More
The Senate Finance Committee hearing on corporate tax reform included the usual discussion about the high tax rate imposed on companies in the U.S., but the committee's chairman, Orrin Hatch (R-Utah), said he is still focused on a proposal to allow corporations to deduct dividends paid to shareholders, a move he said would serve as "a complement to a statutory corporate tax rate reduction, not a substitute." Read More
Before making a mad dash to follow Allergan plc's lead in handing off key patents to an Indian tribe to avoid inter partes reviews (IPRs), other drug and med-tech companies may want to watch from the sidelines to see how the U.S. Supreme Court rules in a case that could doom the entire IPR process. Read More
